You are here

Cardiovascular and Metabolic

cardiovascular-and-metabolic-diseases
Cardiovascular diseases (CVD) remain the leading cause of global mortality, accounting for one in every two adult deaths worldwide. The rates of CVD-related morbidity, including heart-failure, peripheral arterial disease and nephropathy are increasing as more patients survive hearts attacks, and the population ages. In addition, Metabolic Diseases, specifically Type 2 diabetes (T2D) and obesity, are major health problems that have reached epidemic proportions worldwide. Globally T2D and obesity incidence have more than doubled in the past two decades. Importantly, CVD and T2D impose large economic burdens on the individual patient and on national healthcare systems and economies. Pfizer scientists are eager to work with world-class partners who share our mission to develop novel and differentiated medicines to improve the lives of patients suffering from CVD.

Pfizer is interested in partnering to develop therapeutics, expand our understanding of disease biology, and identify biomarkers that can help us impact:

  • CVD (Heart failure, dislipidemia, and atherosclerosis)
  • ƒ Diabetes and related co-morbidities
  • ƒ Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH) and cirrhosis
  • ƒ Obesity and related co-morbidities

Specific areas of interest include:

  • ƒ Preventing cardiac remodeling that is associated with heart failure
  • ƒ Preventing heart failure via anti-inflammatory pathways
  • ƒ ƒ Improving cardiac performance via myocardial protection or repair or improved myocardial perfusion and energetics
  • ƒ ƒ Primary and secondary prevention of cardiovascular events in high-risk patients (T2D, end stage renal disease, and highest-risk sub-groups post-acute coronary syndrome)
  • ƒ Primary and secondary prevention of cardiovascular events in high-risk patients (T2D, end stage renal disease, and highest-risk sub-groups post-acute coronary syndrome)
  • ƒ Novel therapies that reduce hyperinsulinemia and hyperglycemia
  • ƒ Decreasing hepatic lipid content and inflammation and the development of liver fibrosis in patients with NASH/NAFLD
  • ƒ Addressing obesity and eating disorders to induce and sustain weight loss
  • ƒ Brain signals that regulate energy homeostasis and metabolism
  • ƒ Centrally-acting anorectics

Not actively seeking partnering opportunities in:

  • Anti-thrombotics
  • Anti-arrhythmics
  • Stable Angina treatments

R & D Brochure

callout-placeholder

Understand what R&D is looking for in an early stage opportunity.

 

Connect With Us

callout-placeholder

Reach out. We want to hear from you.